Uroprotectants Market
Number of pages: 100 | Report Format: PDF | Published date: April 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
5.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Route of Administration, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global uroprotectants market is expected to grow at a revenue CAGR of 5.2% from 2023 to 2031.
Uroprotectants Market Fundamentals
Uroprotectants are a class of drugs used to prevent or reduce the severity of hemorrhagic cystitis, particularly in patients receiving chemotherapy drugs that can cause this condition. One of the most commonly used uroprotectants for this purpose is Mesna. This synthetic compound works by binding to and neutralizing the toxic metabolites of ifosfamide and cyclophosphamide before they can damage the bladder lining. Mesna is usually administered intravenously before and after treatment with ifosfamide or cyclophosphamide, and it is highly effective in reducing the risk of hemorrhagic cystitis. When the body metabolizes ifosfamide, it breaks down into a harmful substance called acrolein, which can accumulate in the bladder and cause damage to its lining. Mesna can bind with acrolein and other urotoxic metabolites, creating a conjugate that inactivates the harmful compounds and converts them into harmless metabolites. This process helps reduce the risk of hemorrhagic cystitis and other urinary tract complications that can occur due to treatment with ifosfamide.
Uroprotectants Market Dynamics
Cancer incidence is increasing worldwide, leading to an increase in the use of chemotherapy drugs and other cancer treatments. This, in turn, has increased the demand for uroprotectants, which are widely used to prevent hemorrhagic cystitis, a common side effect of chemotherapy drugs such as ifosfamide and cyclophosphamide. According to GLOBOCAN 2020 report, approximately 10 million deaths were caused by cancer in 2020. Advancements in technology have led to the development of new and innovative uroprotectants, such as nanoparticles and other drug delivery systems, that can improve the efficacy and safety of uroprotective agents, propelling revenue growth in the uroprotectants market. With the increasing emphasis on personalized medicine, there is a growing interest in developing uroprotectants tailored to individual patient needs. This includes genetic testing to identify patients at higher risk of developing urinary tract complications and the development of targeted therapies that can provide personalized uroprotection. While Mesna remains the gold standard for uroprotection, research, and development of new uroprotectants may offer further advantages, such as increased efficacy or reduced side effects.
Additionally, patient safety has become a major concern for healthcare providers and regulatory agencies, leading to an increased emphasis on using uroprotectants to prevent urinary tract complications. The rising focus on patient safety is expected to continue to drive uroprotectants demand in the future. There is a growth in collaborations and partnerships between pharmaceutical companies and research organizations to develop new and innovative uroprotective agents. Such uroprotectants market trend is expected to continue as companies seek to expand their product portfolios and meet the growing demand for drugs.
Although uroprotectants are generally considered safe and well-tolerated, they can cause side effects such as nausea, vomiting, constipation, anorexia, and abdominal pain, which may restrict the uroprotectants market revenue growth. Moreover, the high drug cost and stringent regulations are also hindering the growth of the uroprotectants market revenue.
Uroprotectants Market Ecosystem
The global uroprotectants market is analyzed from three perspectives: indication, route of administration, and region.
Uroprotectants Market by Indication
[345]
Based on the indication, the global uroprotectants market is segmented into blood cancer, gynecological cancer, bone cancer, bladder cancer, and others.
The bladder cancer segment accounted for the largest global uroprotectants market revenue share in 2022. The rising prevalence of bladder cancer globally has resulted in a growing demand for uroprotectants, particularly for preventing chemotherapy-associated hemorrhagic cystitis. According to the WHO, bladder cancer is the tenth most prevalent type of cancer globally. Every year, around 600,000 people worldwide are diagnosed with bladder cancer, and more than 200,000 people die as a result of this disease. Chemotherapy is a common bladder cancer treatment; uroprotectants such as Mesna are often used prophylactically to prevent hemorrhagic cystitis. Therefore, their use as a standard of care for bladder cancer treatment is increasing the demand for uroprotectants.
The blood cancer segment accounted for a notable uroprotectants market revenue share in 2022. Leukemia and lymphoma are among the most common types of blood cancers, and their incidence is increasing globally. This high incidence of blood cancers has increased the demand for uroprotectants, particularly for preventing chemotherapy-induced urinary tract complications. According to the WHO, in 2020, around 474,519 new leukemia cases were diagnosed globally, and approximately 311,594 deaths were caused by leukemia. Blood cancers are often treated with high-dose chemotherapy, which can increase the risk of urinary tract complications. Mesna is often used prophylactically to reduce this risk, driving demand in this market segment. With an increasing understanding of the importance of preventing chemotherapy-associated complications, there has been a growing adoption of uroprotectants in treating blood cancer. This adoption has contributed to the revenue growth of the blood cancer segment in the uroprotectants market.
Uroprotectants Market by Route of Administration
Based on the route of administration, the global uroprotectants market is segmented into oral and intravenous.
The intravenous (IV) segment dominated the uroprotectants market with the largest revenue share in 2022. Intravenous administration is a common route of drug administration in hospitals and clinics, particularly for chemotherapy. Since uroprotectants are used prophylactically to prevent chemotherapy-associated urinary tract complications, the IV route of administration is often preferred. Uroprotectants administered intravenously have better bioavailability compared to oral administration, as the drug bypasses the gastrointestinal tract and is delivered directly into the bloodstream. This leads to more efficient and predictable absorption, which is important in the prophylactic use of uroprotectants. Intravenous administration allows for a rapid onset of action, which is important in the prophylactic use of uroprotectants. This is particularly relevant in the case of chemotherapy, where the uroprotectants must be administered before the chemotherapy to prevent urinary tract complications, thus propelling the segmental revenue growth.
Oral uroprotectants, on the other hand, are easy to take and can be self-administered by patients, making them more convenient compared to other forms of uroprotectants that require administration by a healthcare professional. Some oral uroprotectants have been available longer and have a well-established track record of efficacy and safety, which may make them more popular among patients and healthcare providers. Oral uroprotectants may be less expensive than intravenous forms, making them more affordable for patients.
Uroprotectants Market by Region
Based on region, the global uroprotectants market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the global uroprotectants market size in terms of revenue growth. The rising incidence of cancer, particularly bladder and prostate cancer, drives the demand for uroprotectants in North America. Patients receiving chemotherapy and radiation therapy for cancer treatment are at risk of developing bladder and urinary tract damage, which can be prevented or treated with uroprotectants. According to the American Cancer Society, in the U.S., males have a 1 in 28 chance of developing this cancer during their lifetime, whereas women have a probability of roughly 1 in 91. North America has rapidly aging population is more prone to cancer and other diseases requiring chemotherapy and radiation therapy. This is expected to increase the demand for uroprotectants in the region. According to the American Cancer Society, older people are more likely to develop bladder cancer. In the U.S., 9 out of 10 patients with this cancer are older than 55. People are typically 73 years old when they receive a diagnosis. Advancements in urological imaging and diagnosis techniques, such as cystoscopy and urodynamic testing, are improving the diagnosis and management of urological cancers. This drives the demand for uroprotectants as part of the overall treatment regimen. High healthcare expenditure in North America enables more patients to access uroprotectants and other treatments for urological conditions. Increasing awareness among patients and healthcare providers about the benefits of uroprotectants in preventing and treating bladder and urinary tract damage drives the demand for these products. The regulatory environment supports the development and approval of uroprotectants, which drives innovation in the market and increases the availability of these products.
Asia Pacific has the fastest growth rate in terms of the uroprotectants market during the forecast period. The growing occurrence of cancer in the Asia Pacific region fuels the demand for uroprotectants. Patients undergoing cancer treatment with chemotherapy and radiation are vulnerable to the bladder and urinary tract damage, which can be mitigated or treated with uroprotectants. According to the WHO, in 2020, approximately 9,503,710 new cancer cases were diagnosed in Asia Pacific, and about 5,809,431 deaths were caused due to cancer. Progress in urological imaging and diagnosis methods, such as urodynamic testing and cystoscopy, is enhancing the identification and control of urological disorders in Asia Pacific. This stimulates the use of uroprotectants as a component of the comprehensive treatment protocol. The escalating healthcare spending in the Asia Pacific is facilitating greater patient access to uroprotectants and other remedies for urological ailments. With Asia Pacific's aging population, which is more susceptible to cancer and conditions requiring chemotherapy and radiation therapy, the demand for uroprotectants in the region is projected to surge. Additionally, the rising awareness among healthcare providers and patients about the advantages of uroprotectants in averting and managing bladder and urinary tract damage is boosting the demand for these products in the Asia Pacific. The regulatory landscape in the Asia Pacific is evolving to be more conducive to advancing and endorsing uroprotectants. This fosters innovation in the market and augments the accessibility of these offerings.
Uroprotectants Market Competitive Landscape
The prominent players operating in the global uroprotectants market are:
Uroprotectants Strategic Developments
Uroprotectants are a class of drugs used to prevent or reduce the severity of hemorrhagic cystitis, particularly in patients receiving chemotherapy drugs that can cause this condition.
The rising prevalence of cancer globally and growing R&D related to uroprotectants are some driving factors in market revenue.
The prominent players operating in the global uroprotectants market are Baxter International Inc., Fresenius Kabi AG, Athenex, Inc., Teva Pharmaceutical Industries Ltd., and Sagent Pharmaceuticals, among others.
The bladder cancer segment dominated the global uroprotectants market with the largest revenue share.
The high cost related to uroprotectants and the side effects associated with uroprotectants is some of the restricting factors of the market revenue.
*Insights on financial performance are subject to the availability of information in the public domain